Steven Simonson

Chief Tech/Sci/R&D Officer presso WINDTREE THERAPEUTICS, INC.

Patrimonio netto: 6 176 $ in data 31/03/2024

65 anni

Health Technology

Consumer Services

Posizioni attive di Steven Simonson

Società	Posizione	Inizio	Fine
WINDTREE THERAPEUTICS, INC.	Chief Tech/Sci/R&D Officer	01/10/2014	-
WINDTREE THERAPEUTICS, INC.	Corporate Officer/Principal	20/05/2014	01/10/2014

Società	Posizione	Inizio	Fine
AGENNIX AG	Chief Tech/Sci/R&D Officer	18/04/2011	18/04/2011
AGENNIX AG	Corporate Officer/Principal	02/07/2012	01/11/2012
Agennix, Inc. Agennix, Inc. Pharmaceuticals: MajorHealth Technology Agennix, Inc. develops drugs for the treatment of cancer and wound healing. It develops liquid formulation of talactoferrin for cancer indications and a topical gel formulation for the treatment of diabetic foot ulcers. The company is headquartered in Houston, TX.	Corporate Officer/Principal	-	01/11/2012
COVANCE INC.	Corporate Officer/Principal	-	-

The Medical College of Wisconsin, Inc.	Doctorate Degree
Duke University School of Medicine	Graduate Degree

Distribuzione geografica

Stati Uniti	6
Germania	2

Posizioni

Corporate Officer/Principal	4
Chief Tech/Sci/R&D Officer	2
Doctorate Degree	1

Settori

Health Technology	5
Consumer Services	3

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	1
WINDTREE THERAPEUTICS, INC.	Health Technology

Aziende private	3
Labcorp Drug Development, Inc. Labcorp Drug Development, Inc. Pharmaceuticals: MajorHealth Technology Covance, Inc. operates as a contract research organization and drug development company. Its services include research, lead optimization, analysis services, safety assessment and drug safety testing, consulting and partnering, clinical development, informatics, clinical testing, commercialization, and manufacturing support. The company was founded on November 12, 1996 and is headquartered in Princeton, NJ.	Health Technology
Agennix, Inc. Agennix, Inc. Pharmaceuticals: MajorHealth Technology Agennix, Inc. develops drugs for the treatment of cancer and wound healing. It develops liquid formulation of talactoferrin for cancer indications and a topical gel formulation for the treatment of diabetic foot ulcers. The company is headquartered in Houston, TX.	Health Technology
Agennix AG Agennix AG BiotechnologyHealth Technology Agennix AG was a pharmaceutical company, which engaged in the development of protein-based drugs for oncology, asthma and wound healing. Its clinical development programs included oral talactoferrin alfa and RGB-286638. The company was founded in 1993 and was headquartered in Heidelberg, Germany.	Health Technology